ETFs

ETF (UCITS compliant)

L&G Pharma Breakthrough UCITS ETF

USD Accumulating ETF Class

ISINIE00BF0H7608

Price

TER0.49%

Fund aim

The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index").

Fund snapshot

  • Long-term allocation

Long-term value in a pharmaceutical sub-sector that benefits from certain commercial and regulatory incentives

  • High growth potential

Aims to capture the future growth opportunity in orphan drugs

  • Leveraging industry expertise

An index tracking investment strategy that is supported by a team of pharmaceutical experts

  • Does it have a sustainable objective?

The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.

Fund facts

Fund size$25.2m
Base currencyUSD
Fund launch date15 Dec 2017
DomicileIreland
Share class launch23 Jan 2018
Replication methodPhysical - backed by equities
As at 13 Feb 2024

Benchmark

Solactive Pharma Breakthrough Value Index

Index description

Solactive Pharma Breakthrough Value Index Net TR USD

The Index is comprised of bio-technology companies which are publicly traded on various stock exchanges around the world that are actively engaged in the research, development and manufacture of orphan drugs. An “orphan drug” is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. A company is only eligible for inclusion in the Index if (1) it is of a sufficient size (determined by reference to the total market value of the proportion of its shares that are publicly traded) and (2) it is sufficiently “liquid” (a measure of how actively its shares are traded on a daily basis).

The universe of companies out of which the Index selection is made is refreshed annually in April. However, the Index is reconstituted semi-annually in April and October in accordance with the full selection criteria and all companies are equally weighted within the Index. On a monthly basis, the weight of each company is assessed and, if any of them exceeds 15% of the Index, the weights of all companies are adjusted so that they are again equally weighted within the Index.

Index data

ProviderSolactive
Bloomberg codeSOLBIOT
Reuters code.SOLBIOT
TypeNet Total Return
WebsiteGo to website

Performance

Performance for the USD Accumulating unit class in USD, launched on 23 January 2018. Source: Lipper. Performance assumes all ETF charges have been taken and that all income generated by the investments, after deduction of tax, remains in the ETF.
Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. It can help you to assess how the fund has been managed in the past. The tables and charts above shows the fund's performance as the percentage loss or gain per year over the last 10 years.
Share class launch date:23 Jan 2018
Benchmark:Solactive Pharma Breakthrough Value Index Net TR USD
Share class launch date:23 Jan 2018
Benchmark:Solactive Pharma Breakthrough Value Index Net TR USD
    Share class launch date:23 Jan 2018
    Benchmark:Solactive Pharma Breakthrough Value Index Net TR USD

    Performance scenarios

    The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.
    What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.
    The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product with input from the over the last 10 years. Markets could develop very differently in the future.

    Example investment:10,000 USD

    Scenarios1 year(Recommended holding period) 5 years
    Minimum

    There is no minimum guaranteed return. You could lose some or all of your investment.

    Stress scenario
    What you might get back after costs2,140USD1,850USD
    Average return each year (%)-78.60USD-28.68USD
    Unfavourable scenario
    What you might get back after costs7,890USD7,610USD
    Average return each year (%)-21.13USD-5.32USD
    Moderate scenario
    What you might get back after costs10,620USD14,150USD
    Average return each year (%)6.21USD7.19USD
    Favourable scenario
    What you might get back after costs14,020USD17,770USD
    Average return each year (%)40.18USD12.19USD

    Portfolio breakdown

    Top 10 constituents38.0%
    Rest of Index62.0%
    No. of constituents in Index32

    Top 10 constituents (%)

    Swedish Orphan Biovitrum4.5
    Chugai Pharmaceutical4.1
    Ionis Pharmaceuticals4.0
    Innovent Biologics4.0
    PharmaMar3.8
    Sino Biopharmaceutical3.8
    Vertex Pharmaceuticals3.8
    Zai Lab3.4
    InnoCare Pharma3.4
    BioMarin Pharmaceutical3.4

    Sector (%)

    Health Care
    100.0

    All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding. The breakdowns shown relate to the Index. The ETF’s portfolio may deviate from the portfolio of the Index.

    Fund managers

    LGIM Index Fund Management Team headshot

    LGIM Index Fund Management Team

    The Index Fund Management team comprises 25 fund managers, supported by two analysts. Management oversight is provided by the Global Head of Index Funds. The team has average industry experience of 15 years, of which seven years has been at LGIM, and is focused on achieving the equally important objectives of close tracking and maximising returns.

    Sustainability

    SFDR categorisation

    The sustainable investment objective of the Fund is to provide exposure to the global orphan drugs industry. The Fund and seeks to achieve its investment objective by tracking the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.

    Literature

    Prices

    Pricing information

    Price time16:00 EST (NY)
    CurrencyUSD
    Monthly price history

    Download full price history

    Listings and codes

    Listings

    ExchangeCurrencyTickerISINBloombergReutersListing dateTrading hours (local)
    London Stock Exchange
    GBPBIGTIE00BF0H7608BIGT LNBIGT.L23/01/201808:00 - 16:30
    London Stock Exchange
    USDBIOTIE00BF0H7608BIOT LNGEBIOT.L23/01/201808:00 - 16:30
    Borsa Italiana
    EURBIOTIE00BF0H7608BIOT IMECBIOT.MI23/02/201809:00 - 17:30
    Deutsche Börse Xetra
    EURETLIIE00BF0H7608ETLI GYETLI.DE06/02/201809:00 - 17:30
    Euronext Amsterdam
    EURBIOTIE00BF0H7608BIOT NAGOBIOT.AS01/02/201809:00 - 17:30
    SIX Swiss Exchange
    CHFBIOTIE00BF0H7608BIOT SWBIOTC.S05/06/202009:00 - 17:30

    Codes

    ISINIE00BF0H7608
    SEDOLBF0H760
    BloombergBIOT
    MEX-

    Dealing information

    IssuerLegal & General UCITS ETF Plc
    Depositary and TrusteeThe Bank of New York Mellon SA/NV, Dublin Branch
    Securities regulatorCentral Bank of Ireland

    Country registration

    This share class is registered for sale in the following countries:

    Austria
    Denmark
    Finland
    France
    Germany
    Ireland
    Italy
    Luxembourg
    Netherlands
    Norway
    Spain
    Sweden
    Switzerland
    United Kingdom